Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 5/2017

01.05.2017 | Spondyloarthritis (M Khan, Section Editor)

Ankylosing Spondylitis: HLA-B*27-Positive Versus HLA-B*27-Negative Disease

verfasst von: Nurullah Akkoç, Handan Yarkan, Gökçe Kenar, Muhammad A. Khan

Erschienen in: Current Rheumatology Reports | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We review our current knowledge about the clinical features of patients with ankylosing spondylitis (AS) who possess HLA-B*27 versus those who lack this gene.

Recent Findings

ERAP1 association is present only in HLA-B*27+ patients, but other genetic associations are similar between the two groups. A genetic study supports the existence of an HLA-B27-independent common link between gut inflammation and AS. It is unusual to observe familial occurrence of primary AS among families of northern European extraction that show no segregation of HLA-B*27, psoriasis, or IBD.

Summary

Although there are many similarities among AS patients possessing HLA-B*27 versus those lacking this gene, the former group has a younger age of onset, a shorter delay in diagnosis, a better clinical response to tumor necrosis factor inhibitors, a greater familial occurrence, a greater risk for occurrence of acute anterior uveitis, and a lower risk for occurrence of psoriasis and IBD. ERAP1 association is present only in HLA-B*27+ patients, but other genetic associations are similar between the two groups. It is unusual to observe occurrence of primary AS among families of northern European extraction that show no segregation of HLA-B*27, IBD, or psoriasis. A recent genetic study supports the existence of an HLA-B*27-independent common link between gut inflammation and AS.
Literatur
1.
Akkoc N, Khan MA. Epidemiology of ankylosing spondylitis and related spondyloarthropathies. In: Weisman MH, Reveille JD, van der Heijde D, editors. Ankylosing spondylitis and the spondyloarthropathies. St. Louis: Mosby; 2006. p. 117–31.
2.
3.
Caffrey MF, James DC. Human lymphocyte antigen association in ankylosing spondylitis. Nature. 1973;242(5393):121.CrossRefPubMed
4.
5.
Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet. 1973;1(7809):904–7.CrossRefPubMed
6.
7.
Khan MA. An update on the genetic polymorphism of HLA-B27 (HLA-B*27), comprising 204 alleles and 155 subtypes (and still counting). Curr Rheumatol Rep. 2017;In Press.
8.
•• Khan MA. Ankylosing spondylitis—axial Spondyloarthritis West Islip. New York: PCI (Professional Communications, Inc); 2016. Excellent handbook providing comprehensive yet concise up-to- date information on all aspects of axial spondyloarthritis, with particular emphasis on current treatment options including the latest biologic therapies.
9.
10.
•• Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48(5):510–8. doi:10.​1038/​ng.​3528. This global study investigating the pleiotropy and the relationship between five common, inflammatory diseases that commonly occur together in families and in individuals showed that these conditions similar genetic backgrounds. CrossRefPubMedPubMedCentral
11.
12.
13.
Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005;52(4):1000–8. doi:10.​1002/​art.​20990.CrossRefPubMed
14.
Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–76. doi:10.​1038/​nm.​2817.CrossRefPubMed
15.
16.
17.
• Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis - insights into pathogenesis. Nat Rev Rheumatol. 2015;advance online publication. doi:10.​1038/​nrrheum.​2015.​133. This paper provides a comprehensive review of the recent progress in AS genetics and describes how the recently discovered genetic associations has expanded our understanding of its pathogenesis and led to the development of novel therapeutic strategies.
18.
19.
Haroon N, Tsui FW, Uchanska-Ziegler B, Ziegler A, Inman RD. Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis. Ann Rheum Dis. 2012;71(4):589–95. doi:10.​1136/​annrheumdis-2011-200347.CrossRefPubMed
20.
International Genetics of Ankylosing Spondylitis C, Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45(7):730–8. doi:10.​1038/​ng.​2667.CrossRef
21.
Keidel S, Chen L, Pointon J, Wordsworth P. ERAP1 and ankylosing spondylitis. Curr Opin Immunol. 2013;25(1):97–102.CrossRefPubMed
22.
Reeves E, Colebatch-Bourn A, Elliott T, Edwards CJ, James E. Functionally distinct ERAP1 allotype combinations distinguish individuals with ankylosing spondylitis. Proc Natl Acad Sci. 2014;111(49):17594–9.CrossRefPubMedPubMedCentral
23.
Khan MA, Magrey M. Gene–gene interactions of HLA-B27 and ERAP1 in ankylosing spondylitis: finding the pieces of the puzzle. Int J Clin. 2014;9(6):539–42.
24.
Hersh AH, Stecher RM, Solomon WM, Wolpaw R, Hauser H. Heredity in ankylosing spondylitis; a study of fifty families. Am J Hum Genet. 1950;2(4):391–408.PubMedPubMedCentral
25.
van der Linden S, Valkenburg H, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a family and population study. Br J Rheumatol. 1983;22(4 Suppl 2):18–9.CrossRefPubMed
26.
27.
Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2000;59(11):883–6.CrossRefPubMedPubMedCentral
28.
29.
Hochberg MC, Bias WB, Arnett Jr FC. Family studies in HLA-B27 associated arthritis. Medicine (Baltimore). 1978;57(5):463–75.CrossRef
30.
• Yang M, Xu M, Pan X, Hu Z, Li Q, Wei Y, et al. Epidemiological comparison of clinical manifestations according to HLA-B*27 carrier status of Chinese ankylosing spondylitis patients. Tissue Antigens. 2013;82(5):338–43. doi:10.​1111/​tan.​12186. This nationwide epidemiological study from China investigated and reported on the clinical diversity between HLA-B27+ and HLA-B27− AS patients. CrossRefPubMed
31.
Chung HY, Machado P, van der Heijde D, D’Agostino MA, Dougados M. HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Ann Rheum Dis. 2011;70(11):1930–6. doi:10.​1136/​ard.​2011.​152975.CrossRefPubMed
32.
Sampaio-Barros PD, Bertolo MB, Kraemer MH, Neto JF, Samara AM. Primary ankylosing spondylitis: patterns of disease in a Brazilian population of 147 patients. J Rheumatol. 2001;28(3):560–5.PubMed
33.
34.
Paardt M, Dijkmans B, Giltay E, van der Horst-Bruinsma I. Dutch patients with familial and sporadic ankylosing spondylitis do not differ in disease phenotype. J Rheumatol. 2002;29(12):2583–4.PubMed
35.
36.
de Vlam K, Vastesaeger N, Brasseur J, Boonen A, Lenaerts J, Lesaffre E, et al. Belgian patients with familial and sporadic ankylosing spondylitis differ in disease phenotype. Arthritis Rheum. 2006;54:S717–8.
37.
Calin A, Kennedy LG, Edmunds L, Will R. Familial versus sporadic ankylosing spondylitis. Two different diseases? Arthritis Rheum. 1993;36(5):676–81.CrossRefPubMed
38.
Almodovar R, Font P, Zarco-Montejo P, Collantes E, Mulero J, Gratacos J, et al. Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). Clin Exp Rheumatol. 2011;29(5):822–7.PubMed
39.
Chou CT, Lin KC, Wei JC, Tsai WC, Ho HH, Hwang CM, et al. Study of undifferentiated spondyloarthropathy among first-degree relatives of ankylosing spondylitis probands. Rheumatology (Oxford). 2005;44(5):662–5. doi:10.​1093/​rheumatology/​keh577.CrossRef
40.
Joshi R, Reveille JD, Brown MA, Weisman MH, Ward MM, Gensler LS, et al. Is there a higher genetic load of susceptibility loci in familial ankylosing spondylitis? Arthritis Care Res (Hoboken). 2012;64(5):780–4. doi:10.​1002/​acr.​21601.CrossRef
41.
Khan MA, Kushner I, Braun WE, Zachary AA, Steinberg AG. HLA--B27 homozygosity in ankylosing spondylitis: relationship to risk and severity. Tissue Antigens. 1978;11(5):434–8.CrossRefPubMed
42.
Jaakkola E, Herzberg I, Laiho K, Barnardo MC, Pointon JJ, Kauppi M, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis. 2006;65(6):775–80. doi:10.​1136/​ard.​2005.​041103.CrossRefPubMed
43.
Kim TJ, Na KS, Lee HJ, Lee B, Kim TH. HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4):574–9.
44.
Suarez-Almazor ME, Russell AS. B27 homozygosity and ankylosing spondylitis. J Rheumatol. 1987;14(2):302–4.PubMed
45.
Arnett Jr FC, Schacter BZ, Hochberg MC, Hsu SH, Bias WB. Homozygosity for HLA-B27. Impact on rheumatic disease expression in two families. Arthritis Rheum. 1977;20(3):797–804.CrossRefPubMed
46.
•• Kim T-J, Sung I-H, Lee S, Joo KB, Choi JH, Park D-J, et al. HLA-B27 homozygosity has no influence on radiographic damage in ankylosing spondylitis: Observation Study of Korean spondyloArthropathy Registry (OSKAR) data. Joint Bone Spine. 2013;80(5):488–91. doi:10.​1016/​j.​jbspin.​2012.​12.​003. This study, with the largest number of HLA-B*27 homozygous cases with AS, found no role for HLA-B*27 homozygosity on the structural progression in this disease.
47.
Linssen A. B27+ disease versus B27- disease. Scand J Rheumatol Suppl. 1990;87:111–8. discussion 8–9CrossRefPubMed
48.
49.
50.
Van der Linden JM, De Ceulaer K, Van Romunde LK, Cats A. Ankylosing spondylitis without HLA B27. J Rheumatol Suppl. 1977;3:54–6.PubMed
51.
Khan MA, Kushner I, Braun WE. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum. 1977;20(4):909–12.CrossRefPubMed
52.
Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23(2):61–6. doi:10.​1007/​s00296-002-0237-4.PubMed
53.
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60(3):717–27. doi:10.​1002/​art.​24483.CrossRefPubMed
54.
Dougados M, d’Agostino MA, Benessiano J, Berenbaum F, Breban M, Claudepierre P, et al. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint, bone, spine : revue du rhumatisme. 2011;78(6):598–603. doi:10.​1016/​j.​jbspin.​2011.​01.​013.CrossRef
55.
Lee JH, Jun JB, Jung S, Bae SC, Yoo DH, Kim TY, et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci. 2002;17(5):669–73.CrossRefPubMedPubMedCentral
56.
Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol. 1994;21(10):1883–7.PubMed
57.
58.
59.
Nahir M, Scharf Y, Brik R, Scharf Y, Gidoni O, Barzilai A. The influence of HL-A B27 on the clinical picture of ankylosing spondylitis. Rheumatol Rehabil. 1979;18(1):10–2.
60.
61.
Queiro R, Sarasqueta C, Belzunegui J, Gonzalez C, Figueroa M, Torre-Alonso JC. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum. 2002;31(6):413–8.CrossRefPubMed
62.
Armstrong RD, Panayi GS, Welsh KI. Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann Rheum Dis. 1983;42(2):142–6.CrossRefPubMedPubMedCentral
63.
64.
Braun J, Rudwaleit M, Kary S, Kron M, Wong RL, Kupper H. Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology (Oxford). 2010;49(8):1578–89. doi:10.​1093/​rheumatology/​keq129.CrossRef
65.
66.
67.
Voulgari PV. Rheumatological manifestations in inflammatory bowel disease. Ann Gastroenterol. 2011;24(3):173–80.PubMedPubMedCentral
68.
Mielants H, Veys EM, Cuvelier C, De Vos M. Subclinical involvement of the gut in undifferentiated spondylarthropathies. Clin Exp Rheumatol. 1989;7(5):499–504.PubMed
69.
Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002;29(3):511–5.PubMed
70.
71.
Brophy S, Hickey S, Menon A, Taylor G, Bradbury L, Hamersma J, et al. Concordance of disease severity among family members with ankylosing spondylitis? J Rheumatol. 2004;31(9):1775–8.PubMed
72.
73.
Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis. 2015;74(7):1387–93. doi:10.​1136/​annrheumdis-2013-204835.CrossRefPubMed
74.
Boonen A, vander Cruyssen B, de Vlam K, Steinfeld S, Ribbens C, Lenaerts J, et al. Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol. 2009;36(6):1249–55. doi:10.​3899/​jrheum.​080831.CrossRefPubMed
75.
Ward MM, Hendrey MR, Malley JD, Learch TJ, Davis Jr JC, Reveille JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum. 2009;61(7):859–66. doi:10.​1002/​art.​24585.
76.
77.
•• Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis. 2013; doi:10.​1136/​annrheumdis-2013-204055. This long term prospective data from the European Outcome in Ankylosing Spondylitis International Study (OASIS) radiographic progression in AS is highly variable in the individual patient, more severe in HLA-B*27-positive male patients and those with a higher existing level of spinal damage present at baseline.
78.
Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis. Arthritis Rheum. 2012;64(5):1388–98. doi:10.​1002/​art.​33465.CrossRefPubMed
79.
Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369–74. doi:10.​1136/​ard.​2010.​145995.CrossRefPubMed
80.
Bennett AN, McGonagle D, O’Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413–8. doi:10.​1002/​art.​24024.CrossRefPubMed
81.
van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46. doi:10.​1002/​art.​21913.CrossRefPubMed
82.
83.
84.
Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J Rheumatol. 2015;42(8):1418–26.CrossRefPubMed
85.
Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36(4):801–8. doi:10.​3899/​jrheum.​081048.CrossRefPubMed
86.
Fagerli KM, Lie E, Heiberg MS, van der Heijde D, Kalstad S, Knut M, et al. Predictors of ASDAS major improvement in patients with ankylosing spondylitis (AS) receiving their first TNF inhibitor: results from a longitudinal observational study. Arthritis Rheum. 2011;63(Suppl 10):533.
87.
88.
Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981–91. doi:10.​1002/​art.​23606.CrossRefPubMed
89.
Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815–22. doi:10.​1136/​annrheumdis-2012-201766.CrossRefPubMed
90.
Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(8):2091–102. doi:10.​1002/​art.​38721.CrossRefPubMed
91.
Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702–12. doi:10.​1002/​art.​39257.CrossRefPubMedPubMedCentral
92.
Thjodleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum. 2007;56(8):2633–9. doi:10.​1002/​art.​22812.CrossRefPubMed
Metadaten
Titel
Ankylosing Spondylitis: HLA-B*27-Positive Versus HLA-B*27-Negative Disease
verfasst von
Nurullah Akkoç
Handan Yarkan
Gökçe Kenar
Muhammad A. Khan
Publikationsdatum
01.05.2017
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 5/2017
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-017-0654-8

Weitere Artikel der Ausgabe 5/2017

Current Rheumatology Reports 5/2017 Zur Ausgabe

Orphan Diseases (B Manger, Section Editor)

Bone Involvement in Rosai-Dorfman Disease (RDD): a Case Report and Systematic Literature Review

Vasculitis (L Espinoza, Section Editor)

Diffuse Alveolar Hemorrhage in Autoimmune Diseases

Scleroderma (J Varga, Section Editor)

Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets

Complementary and Alternative Medicine (S Kolasinski, Section Editor)

Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis

Spondyloarthritis (M Khan, Section Editors)

Treat to Target in Axial Spondyloarthritis: What Are the Issues?

Rheumatoid Arthritis (L Moreland, Section Editor)

Fatigue in Rheumatoid Arthritis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise